The ACTIV4 Host Tissue platform is testing if treatments targeting the host-tissue response to SARS-CoV-2 infection can improve recovery and prevent worsening in patients hospitalized with COVID-19.

The ACTIV4A Inpatient study is testing if treatments that aim to prevent blood vessel injuries and blood clots improve recovery from patients hospitalized due to COVID-19.